Aug 2026· Research Square· 0 citations· 46 references
Medicine
TL;DR
Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes, and support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.
Abstract
Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with melanoma and are now the standard of care for high-risk and advanced disease. However, long-term benefits are observed in only around 25% of patients, with significant risk for immune-related adverse events, highlighting the need for predictive biomarkers. To develop a minimally invasive, pre-treatment biomarker strategy, we profiled functional and subset-specific transcripts in peripheral blood T lymphocytes (PBTLs) and applied machine learning to identify predictive signatures. Patients were enrolled prior to receiving ICI monotherapy in the adjuvant (Exploratory n=61, Validation=78) or metastatic (Exploratory n=48, Validation=46) settings. Following feature selection, random forest models were trained and benchmarked against empirical null models. In the adjuvant setting, CD160 and GZMB predicted recurrence (95th percentile), while treatment-limiting toxicity was predicted by a signature comprising TNFRSF18, VTCN1, TIGIT, CCR4, and AHR (97th percentile). In the metastatic setting, baseline CD45RB, a marker of T-cell differentiation, most strongly predicted progression within one year (93.9th percentile). Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes. These findings support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of TNBC, leading to durable responses and improved survival. With the adoption of immunotherapy into high-risk early-stage and selected metastatic triple-negative breast cancer (TNBC), clinicians’ ability to recognize and treat immune-related adverse...
E. McGillivray, Savannah Kane, Armina Saadatkhah et al.· Frontiers in Immunology· 0 citations
F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.
N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al.· Cell Reports Medicine· 0 citations
Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.
Federica Falcone, E. Pietroluongo, P. De Placido· Current Opinion in Oncology· 0 citations
Findings suggest that biomarkers reflecting reduced inflammation, absence of metastasis and potentially improved nutritional status may be associated with improved PFS and OS in patients with advanced NSCLC receiving ICIs.
Ilse Visser, E. Suazo-Zepeda, T. J. N. Hiltermann et al.· Cancer Treatment and Researc...· 0 citations
Abstract Background Combination immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 antibodies improves outcomes in metastatic renal cell carcinoma (mRCC), yet 40–60% of patients fail to achieve meaningful responses. Robust biomarkers that predict deep and durable responses are lacking. We aimed to define syste...
S. Guglietta, A. Bärenwaldt, Anthony Sonrel et al.· The Oncologist· 0 citations
This review will analyze the current evidence supporting established predictive biomarkers, including PD-L1 expression, while highlighting their major limitations, and discuss and summarize emerging clinical and molecular biomarkers and integrative predictive approaches aimed at improving the stratification of patients...
C. Spagnolo, I. Campo, Elena Fassi et al.· Immunotherapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.